Compare HCA Health Inc (HCA) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs Vale SA — how do they compare? HCA Health Inc trades at $451.09 (market cap $96.35B), while Vale SA trades at $13.62 (market cap $57.32B). The key difference: HCA Health Inc is the larger of the two by market cap, and Vale SA pays the higher dividend (8.87%). Which is the better fit depends on your goals — on Pluang, investors hold HCA Health Inc for 76 Days and Vale SA for 109 Days on average.
| HCA | VALE | |
|---|---|---|
Market Cap | $96.35B | $57.32B |
Volume | 1,079,453 | 27,996,846 |
Sector | Health | Basic Materials |
52-Week High | $545.13 | $17.82 |
52-Week Low | $361.32 | $10.75 |
Typical Hold Time | 76 Days | 109 Days |
Enterprise Value | $146.88B | $73.56B |
Dividend Yield | 0.7% | 8.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare trades at $451.09, up 2.71% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q4 2025 and Q1-Q2 2026 exceeding expectations, supported by robust revenue growth from $70.6B in 2024 to $75.6B in 2025. Valuation metrics remain attractive with P/E of 14.92 and P/S of 1.31, while technical indicators signal bullish momentum above key support levels.
The outlook remains positive with 63% analyst buy ratings and $461.12 consensus target, though legal investigations and high debt levels pose risks. Revenue growth and operational efficiency provide upside potential, but investors should monitor regulatory developments and debt management closely given the 80.9% debt-to-asset ratio in 2025.
VALE trades at $13.62, near recent lows, with a bearish technical outlook and mixed sentiment. The stock has missed earnings expectations in recent quarters, with Q3 2026 EPS expected at $0.4212. Revenue has declined from $43.8B in 2022 to $38.4B in 2025, though 2026 is projected at $41.2B. Net income margin compressed to 5.11% in 2025. Analyst consensus is a 'Hold' with a $16.21 price target, indicating modest upside potential from current levels.
VALE faces headwinds from cyclical commodity exposure and cost inflation, but its base metals segment shows growth. Investment appeal hinges on iron ore price stability and execution on cost controls. Risks include regulatory challenges in Brazil and volatile raw material markets. The stock offers a dividend yield but requires careful monitoring of earnings trajectory and macroeconomic factors affecting mining sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
